Kazunari Tsuyuguchi

Kazunari Tsuyuguchi

Auto-generated profile, based on publicly available information

Kazunari Tsuyuguchi

Department of Infectious Disease, Clinical Research Center, National Hospital Organization Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka, 591-8555, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2018 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SISeigo Ishii
Seigo Ishii
ATAkihiro Tamiya
Akihiro Tamiya
YTYoshihiko Taniguchi
Yoshihiko Taniguchi
TTTsunehiro Tanaka
Tsunehiro Tanaka
YAYuko Abe
Yuko Abe
SAShinji Atagi
Shinji Atagi
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 January 2017 in Respiratory Investigation
Verified
Journal Article
Closed access
TTTaisuke Tsuji
Taisuke Tsuji
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
KTKazunobu Tachibana
Kazunobu Tachibana
YKYohei Kimura
Yohei Kimura
TKTakehiko Kobayashi
Takehiko Kobayashi
KSKatsuhiro Suzuki
Katsuhiro Suzuki

28 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
YKYu Kurahara
Yu Kurahara
SYShiomi Yoshida
Shiomi Yoshida
AOAsami Osugi
Asami Osugi
YTYuya Tanaka
Yuya Tanaka
TKTakehiko Kobayashi
Takehiko Kobayashi
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
Background: Amikacin liposome inhalation suspension (ALIS) is key for treating refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, microbiological efficacy by subtype remains unknown. The frequency and mechanism of amikacin (AMK) resistance during ALIS administration are also unclear. Methods: We retrospectively analyzed data from refractory MAC-PD patients who received ALIS for at least 6 months as an adjunct to guideline-based therapy at the NHO Kinki Chuo Chest Medical Center. We investigated the efficacy of ALIS and analyzed gene expression and the frequency of AMK resistance. Results: We enrolled 44 patients (median age, 72.0 years): 19 (43.2%) with the noncavitary nodular bronchiectatic (NC-NB) subtype and 25 (56.8%) with the cavitary subtype. Overall, sputum culture conversion was 56.8% (25/44): 84.2% (16/19) in the NC-NB subtype and 36.0% (9/25) in the cavitary subtype (P = .001). During intermittent dosing, conversion occurred in 50.0% (9/18). In patients with C-reactive protein (CRP) ≥1 mg/dL, cavitary subtype, and clarithromycin (CLM) resistance, the risk ratio for persistently positive cultures was 10.81 (95% CI, 1.66–70.40) compared with those with CRP <1 mg/dL, NC-NB subtype, and CLM susceptibility. Of all participants, 15.9% (7/44) had isolates with AMK resistance (minimum inhibitory concentration ≥128 µg/mL), and of these 71.4% (5/7) had rrs mutations. Conclusions: Regimens that included ALIS achieved higher culture conversion in NC-NB than cavitary MAC-PD cases. High CRP levels, cavitary disease, and CLM resistance predicted persistent culture positivity. AMK resistance acquired during ALIS administration may limit treatment options for refractory MAC-PD.

1 March 2021 in Respiratory Investigation
Verified
Journal Article
Closed access
SMShojiro Minomo
Shojiro Minomo
TKTakehiko Kobayashi
Takehiko Kobayashi
KKKanako Katayama
Kanako Katayama
MRMisaki Ryuge
Misaki Ryuge
TKTomoko Kagawa
Tomoko Kagawa
KSKatsuhiro Suzuki
Katsuhiro Suzuki

1 September 1998 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
KSKatsuhiro Suzuki
Katsuhiro Suzuki
TKTerumi Kimoto
Terumi Kimoto
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
HMHisako Matsumoto
Hisako Matsumoto
ANAkio Niimi
Akio Niimi
RARyoichi Amitani
Ryoichi Amitani
We report on a patient whose sputum contained both Mycobacterium tuberculosis and Mycobacterium avium complex (MAC). The MAC failed to be detected by the PCR-based AMPLICOR test. The unrecognized coexistence of MAC in the sample modified the results of drug susceptibility tests. Experiments revealed that the presence of both M. tuberculosis and MAC was not detected by the AMPLICOR test under certain conditions.

1 February 2017 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
HNHideaki Nagai
Hideaki Nagai
KOKenji Ogawa
Kenji Ogawa
TMTomoshige Matsumoto
Tomoshige Matsumoto
KMKozo Morimoto
Kozo Morimoto
SMSatoshi Mitarai
Satoshi Mitarai